Agenus to Present at BIO CEO & Investor Conference

  Agenus to Present at BIO CEO & Investor Conference

BIO CEO & Investor Conference 2014

Business Wire

LEXINGTON, Mass. -- February 6, 2014

Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune
system activating treatments for cancers and infectious diseases, today
announced that the company will be presenting at the 16^th Annual BIO CEO &
Investor Conference on Monday, February 10^th at 9:30 am EST in the Conrad
Room. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual
BIO CEO & Investor Conference will take place February 10-11 at the Waldorf
Astoria in New York City.

Web Cast Information

The live and archived webcast of the company presentation will be accessible
from the company’s website at www.agenusbio.com/webcast. Please log in
approximately 5-10 minutes before each event to ensure a timely connection.
The archived replay will be available on the Agenus website for one month
following the conference.

About Agenus

Agenus Inc. is a biotechnology company developing treatments for cancers and
infectious diseases. The company has multiple immunotherapeutic products based
on strong technology platforms that are advancing through the clinic. Agenus’
technology is further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical trials with
corporate partners. Between Agenus and its partners, 23 programs are in
clinical development. For more information, please visit www.agenusbio.com, or
connect with the company on Facebook, LinkedIn, Twitter and Google+. For more
information, please visit www.agenusbio.com.

Forward-Looking Statement

This press release contains forward-looking statements, including statements
regarding clinical trial activities, the publication of data, and the
potential application of the Company’s technologies and product candidates in
the prevention and treatment of diseases. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission for the period ended
September 30, 2013. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus undertakes
no obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement. Agenus’ business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus’ business and
securities, investors should give careful consideration to these risks and
uncertainties.

Contact:

Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and Corporate Communications
jonae.barnes@agenusbio.com
 
Press spacebar to pause and continue. Press esc to stop.